News summaryThe Motley FoolNov 5, 2026, 05:53 PM
ADMA Biologics (ADMA) Q3 2026 Earnings Call Transcript
ADMA reported third-quarter 2026 revenue of $141.1 million. [[fact:fact-okzq563w8]] ASCENIV third-quarter revenue was $124.7 million, up 31% year over year and 21% sequentially. [[fact:fact-i86kp379f]] Third-quarter adjusted EBITDA was $77.3 million, up 32% year over year and 25% sequentially. [[fact:fact-56oic0xuh]] The company raised its minimum full-year adjusted EBITDA guidance from $265 million to $275 million. [[fact:fact-tusiqj14p]] ADMA reiterated its 2026 full-year revenue guidance of at least $530 million. [[fact:fact-wiq1q1v4l]] Days sales outstanding rose to 110 days, above the company's target range of 90 to 105 days. [[fact:fact-dgld5qwtq]]